Pharma: Clinic Roundup
Wednesday, March 6, 2013
UCB SA, of Brussels, Belgium, reported results from a Phase III study showing that lacosamide monotherapy met the primary endpoint, with a significantly lower exit rate in adults with partial-onset seizures with or without secondary generalization compared with historical controls.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.